Biomedicines Submission Guide: MDPI Process (2026)

Biomedicines is not a stronger version of a subscription medicine journal, and it is not a weaker one. It is a different model. MDPI built it around speed and soundness-based review: the editorial question is whether the work is methodologically sound and within scope, not whether it ranks among the most selective findings of the year. That model shapes everything about how you should prepare the package.

Two consequences matter most. First, the journal sits inside a crowded MDPI life-sciences family, so scope fit is assessed not just against "is this biomedicine" but against whether the work belongs here rather than at Cells, International Journal of Molecular Sciences, or Cancers. Second, the pre-check is fast and partly template-driven, so completeness is rewarded and incompleteness is punished early. A technically excellent manuscript with a missing ethics statement can be returned before a reviewer ever sees it, while a competent, complete, in-scope study moves quickly.

The editorial identity that defines Biomedicines is translation. The journal wants the disease to be the protagonist: the mechanism behind it, the therapeutic that addresses it, or the biomarker that tracks it. A paper that describes a molecular phenomenon in a cell line without connecting it to a disease process is closer to International Journal of Molecular Sciences territory; a paper whose center of gravity is cell biology for its own sake fits Cells better. Biomedicines wants the line from molecule to patient drawn explicitly.

The core fit for most submissions is the original research article. It works best when the disease-mechanism or therapeutic question is central, the methods are reproducible from the text, and the functional or validation data is already in the manuscript rather than promised as future work.

Ask these questions before you submit:

• is the disease mechanism, therapeutic, or biomarker the actual subject of the paper, or is it a downstream framing on a basic-biology finding?
• is the central claim anchored by functional or validation data, or does it rest on a single correlation?
• are the ethics, consent, and data statements complete and specific, or are they still stub text?
• would this paper fit a sister MDPI journal (Cells, International Journal of Molecular Sciences) better than Biomedicines?

If the answers are uncertain, the scope-and-mechanism problem is usually more important than the science problem.

The pre-check editor is answering a short list of questions fast.

On scope, the editor asks whether the manuscript belongs in a translational-biomedicine journal rather than a molecular or cell-biology sister title. If the disease relevance is thin or bolted on, the paper is redirected or returned. On mechanism, the question is whether the work explains something rather than merely describing it. Biomedicines does not require the finding to be field-defining, but a purely descriptive association without a functional anchor reads as preliminary, and that is the fastest non-administrative return at the pre-check.

On integrity, the editor checks whether ethics approvals, consent, image-integrity expectations, and data availability are all in order. MDPI runs integrity and plagiarism checks at pre-check, and gaps here trigger fast returns. On completeness, the editor looks for the declarations block. A manuscript missing Author Contributions, Funding, or Conflicts of Interest reads as not ready, even when the science is fine.

Manuscript structure: Biomedicines expects a defined section set: Abstract, Keywords, Introduction, Materials and Methods, Results, Discussion, Conclusions, plus the declarations block. Original research uses a single-paragraph abstract of around 200 words written in structured style (background, methods, results, conclusions) but without headings. The abstract is the first thing the pre-check editor reads, so the disease question and the main mechanistic result both need to be visible there.

Mechanism and validation readiness: Provide full experimental detail so results can be reproduced, and make the functional or validation evidence explicit. A biomarker paper needs an independent validation cohort or a functional readout, not a single discovery-cohort correlation. A therapeutic paper needs a mechanism of action or a dose-response, not just an endpoint. A clinical or translational paper that does not map cleanly onto its reporting guideline (CONSORT, PRISMA, ARRIVE) is the most common reviewer-stage friction point.

Declarations and ethics: Draft the Institutional Review Board statement, Informed Consent statement, Author Contributions (by initials), Funding, Data Availability, and Conflicts of Interest sections before you upload. These are not post-acceptance paperwork at MDPI; they are pre-check gates.

Figures, supplementary, and abstract assets: A graphical abstract is optional but commonly used; if supplied, it should be a high-resolution PNG, JPEG, or TIFF. Supplementary materials should carry the detail that would slow the main narrative, including extended validation data and full statistical tables. ORCID is expected for the submitting author, and the system will ask for suggested reviewers.

In our pre-submission review work with Biomedicines manuscripts, three named rejection patterns generate the most consistent pre-check returns and reviewer friction, and they are testable against your own manuscript before you upload. Each one maps to a specific editorial triage pattern at the MDPI pre-check, not to a vague quality judgment.

Across our Biomedicines pre-submission reviews, the pattern that surprises authors most is that the Biomedicines pre-check is not a quality filter in the Nature sense; it is a mechanism-fit-and-completeness filter. The manuscripts that get returned fastest are rarely bad science. They are competent studies whose disease-mechanism angle, scope fit against the MDPI sister journals, or validation data is not ready for a fast, template-driven screen. Manuscripts coming through pre-submission review for Biomedicines split cleanly along these three lines.

Descriptive disease-association framing with no mechanism

The single most common pattern we see at Biomedicines is a manuscript that reports a correlation and stops. The study finds that a gene, protein, or pathway is up or down in a disease group versus controls, and the discussion speculates about why, but the experiments never test the mechanism or validate the association independently.

Biomedicines is a translational-biomedicine journal, so the pre-check editor is looking for the functional anchor that turns a correlation into a mechanism. When the abstract and Results report only differential expression or a single-cohort association, the work reads as preliminary and is returned or sent back for major revision fast.

The testable version of this failure: read your own abstract, find the main claim, and ask whether the manuscript contains an experiment that tests why the association holds or a second dataset that confirms it.

If the strongest sentence in your Results is "X was significantly higher in patients than controls," with no functional follow-up and no validation cohort, the mechanism is missing and the fix is to add the functional or validation experiment before submission rather than to argue the point harder in the discussion.

Check whether your Biomedicines manuscript has a mechanism, not just a correlation →

Underpowered or single-cohort studies framed as translational

The second pattern is a small, underpowered cohort presented as if it supports a translational claim. We repeatedly see biomarker papers built on a discovery cohort of a few dozen samples with no validation set, retrospective case series presented as evidence for clinical utility, and animal studies with group sizes too small to support the effect-size claims in the abstract.

Translational framing raises the evidence bar: a claim about clinical relevance or therapeutic potential invites reviewers to ask about sample size, statistical power, confounders, and independent validation. The testable version: count the sample size behind your central claim, identify whether there is an independent validation cohort or a power calculation, and check whether the abstract's translational language is actually supported by the n.

If the conclusion says "potential biomarker for early diagnosis" but the evidence is one cohort of 40 with no validation, the framing has outrun the data, and the fix is to either add the validation set or scale the claim down to what the cohort can support.

Check whether your Biomedicines cohort and power support the translational claim →

Scope drift toward a sister MDPI journal (Cells, IJMS)

The third pattern shows up at pre-check as a scope mismatch within the MDPI family. The manuscript is sound, but its center of gravity is basic cell biology or molecular science rather than disease translation, so it fits Cells or International Journal of Molecular Sciences better than Biomedicines.

A study of a signaling pathway in a generic cell line with a disease name attached only in the introduction reads as IJMS-shaped; a study of organelle dynamics or cell-fate decisions for their own sake reads as Cells-shaped. Because MDPI editors can transfer or redirect across the family, a scope-misfit manuscript often gets a "consider transferring to" response that costs you the timeline you submitted to Biomedicines for.

The testable version: read your introduction and ask whether the disease, the therapeutic, or the biomarker is the protagonist, or whether the molecule or the cell is.

If the disease appears only as motivation in the first paragraph and the last paragraph, and the body is pure molecular or cell biology, the manuscript is scope-drifting, and the fix is to either rebuild the narrative around the translational question or submit to the sister journal that actually fits.

Check whether your Biomedicines scope fits here, not a sister MDPI journal →

Each of these is something you can check against your own draft before you commit the submission. This guide tells you what Biomedicines editors look for; the review tells you whether YOUR paper passes the pre-check before you upload. Of the 80+ manuscripts targeting translational and biomedical journals that our team reviewed, including Biomedicines and its open-access peers, these three patterns recur far more often than any technical-quality problem.

Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts. Run a Biomedicines submission package check to see whether your mechanism framing, cohort evidence, and declarations block will clear the MDPI pre-check.

Biomedicines reports a median first decision near 21 days, and SciRev author reports put the first review round close to two weeks with around four review reports per manuscript. Treat these as planning ranges, not promises: clinical and large translational manuscripts often run longer because reviewer search takes time in specialized subfields.

• Day 0: Submission via SuSy. The portal accepts the package and routes it to the handling editor for pre-check.

• Days 1 to 3: Editorial pre-check. The editor screens scope fit, mechanism, ethics completeness, integrity and plagiarism checks, and basic soundness.

The fastest returns happen here, before any reviewer is invited.

• Days 3 to 7: Reviewer invitation. Manuscripts that pass pre-check enter single-blind reviewer search, typically targeting two or more reviewers in the relevant disease or therapeutic area.

• Days 7 to 21: Peer review and first decision. Reviewer reports return and the editor issues the first decision, with a median near 21 days from submission.

Major revision is the most common outcome for papers that clear pre-check.

• Days 21 to 40: Revision and acceptance. Revisions are usually requested on a short clock; resubmission and a second review cycle commonly land acceptance inside a few weeks for in-scope, complete packages.

• Days 40 to 45: Production and publication. MDPI production is fast once a paper is accepted, so the slow part of the calendar is reviewer search and revision, not production.

This guide was researched and built from primary sources: the sources we checked include the Biomedicines Instructions for Authors, the journal's aims-and-scope and editorial-process pages, MDPI's research and publication ethics policy, SciRev author-reported review-timing data, and Manusights pre-submission review patterns from translational manuscripts deciding between Biomedicines and peer open-access biomedicine journals. We reviewed and compared current MDPI author guidance with recent Manusights work reviews from authors weighing Biomedicines, Cells, International Journal of Molecular Sciences, Journal of Translational Medicine, and BMC Medicine. Last reviewed by the Manusights editorial team on 2026-06-07.

Source limitations: MDPI can update APC, article-format details, abstract caps, and editorial-process numbers after this review date, so verify final administrative details against the official Biomedicines author pages before upload. Median timelines are reported by the journal and by SciRev and vary by subfield. Use this guide for the decision the official instructions cannot answer: whether your mechanism framing, cohort evidence, and reporting completeness are ready for the MDPI pre-check.

• Biomedicines journal overview and metrics
• International Journal of Molecular Sciences submission guide
• Cells submission guide
• BMC Medicine submission guide
• BMC Medicine journal metrics
• Rejected from BMC Medicine, where next?

Before you upload, run your manuscript through a Biomedicines submission readiness check to catch the mechanism, cohort, and scope gaps the MDPI pre-check filters for. The check is free to run (/ai-review) and takes a single upload.